TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
NGNE

Neurogene Inc

Healthcare · Biotechnology · —

33.60$ +3.2% vs. previous close Closing price · As of: Sep 22, 2026

Statements

Balance Sheet

All figures as a percentage of total assets in the same period.

Tick rows to compare them in a chart (up to 4)

Balance Sheet NGNE
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
94.9% 66.0% 67.0% 98.6% 99.4% 97.7% 92.4% 72.9% 77.5% 90.0% 94.1% 94.2%
36.0% 34.9% 20.9% 47.2% 99.1% 97.3% 91.5% 69.5% 75.1% 66.6% 40.7% 36.0%
94.4% 65.7% 66.8% 98.0% 99.1% 97.3% 91.5% 69.5% 75.1% 88.6% 93.1% 93.2%
0.2% 0.0% 0.8% 0.9% 0.3% 0.2%
1.9% 1.0% 0.7%
0.4% 0.2% 0.1%
12.7% 4.3% 6.3% 10.4% 6.4% 3.6% 9.2% 190.5% 9.7% 16.4% 7.6% 8.2%
12.6% 4.2% 6.2% 9.9% 6.0% 3.2% 3.7% 10.7% 6.1% 10.3% 4.5% 5.7%
0.4% 0.3% 1.8% 0.6% 1.3% 0.9% 1.1%
1.8% 0.9% 1.1% 0.6% 5.5% 0.6% 1.2% 0.4% 0.7%
87.3% 95.7% 93.7% 89.6% 93.6% 96.4% 90.8% -90.5% 90.3% 83.6% 92.4% 91.8%
-215.9% -98.2% -96.0% -179.9% -296.4% -203.7% -158.1% -94.2% -138.0% -84.1% -78.1% -122.2%
20.9% 11.2% 12.2% 21.3% 30.3% 18.4% 24.6% 54.2% 11.7% 5.8% 5.2% 7.3%

Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?